MSRB2 and Parkinson disease: Here, we report the identification of two PilB inhibitors in vitro and the validation of their anti-T4P activities in vivo. The inhibitors are benserazide and levodopa, two structurally related compounds approved for combinatorial therapy of Parkinson’s disease (PD).